Swedish Orphan Biovitrum AB (publ) (Sobi®) today announces its results for the fourth quarter and full year of 2021.

Link to report below.

Investors, analysts and media are invited to participate in a conference call, which will include a presentation of the results and a Q&A session at 12:00 CET. The event will in English.

The presentation can be followed live or afterwards on sobi.com. The slides will be made available on sobi.com prior to the conference call.

To participate in the conference call, please call:

Sweden: +46 8 505 583 73 (direct)

UK: +44 3 333 009 272 (direct)

US: +1 631 913 14 22 (toll) PIN: 50558397#

Sobi

Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. Providing sustainable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,600 employees across Europe, North America, the Middle East and Asia. In 2021, revenue amounted to SEK 15.5 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi atsobi.com, LinkedIn and YouTube.

Contacts

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

Ämnen i artikeln


Swedish Orphan Biovitrum

Senast

298,80

1 dag %

0,74%

1 dag

1 mån

1 år

Marknadsöversikt

OMX Stockholm 30

1 DAG %

−1,45%

Senast

2 428,94

1 mån
Loading market data...
Senaste aktieanalyserna på Placera
Kollage Analys Ny
Privatekonomi med Placeras expert
Karolina Palutko Macéus
Karolina Palutko Macéus skriver om allt som har med privatekonomi att göra och hur du kan få mer pengar i plånboken.
Affärsvärlden
AFV
Är du kund hos Avanza? Just nu kan du få en unik rabatt på Affärsvärlden. Afv har 28 år i rad utsetts till Sveriges bästa affärsmagasin i en undersökning med börs-VD:ar, finanschefer, IR-chefer och aktieproffs.
Annons
Introduce
för börsens små- och medelstora företag.
Annons
Investtech
Här hittar du våra artiklar om teknisk analys i samarbete med Investtech.